AZD3463 is an investigational small molecule inhibitor of anaplastic lymphoma kinase (ALK) and insulin-like growth factor 1 receptor (IGF-1R). It is primarily utilized in the field of oncology as a research tool and potential therapeutic agent targeting specific types of cancer driven by ALK gene fusions or mutations, such as certain forms of non-small cell lung cancer (NSCLC). By inhibiting the ALK and IGF-1R proteins, it disrupts the signaling pathways that promote tumor growth, survival, and resistance mechanisms. This compound has been studied in preclinical and early clinical trials to evaluate its efficacy and safety in patients with ALK-positive malignancies. Its potential application extends to overcoming resistance to other ALK inhibitors, offering a therapeutic option for patients who have developed resistance to first-line treatments.